NASHVILLE, Tenn., July 20, 2017 -- Truxton Corporation (OTCPK:TRUX), a financial holding company and the parent of Truxton Trust Company, announced that its Board of Directors has approved a quarterly cash dividend of $0.20 per common share payable September 26, 2017 to shareholders of record as of September 7, 2017.
The Board of Directors has also authorized a stock repurchase program under which the Corporation may repurchase up to $1 million of its common shares during a period beginning after the release of second quarter earnings and extending for one year. The shares may be purchased in open market or private transactions at the discretion of management, subject to the limitations of applicable securities laws.
About Truxton Trust
Truxton Trust is a full-service private bank and trust company founded in 2004. Since its inception, Truxton Trust has been focused on a singular guiding principle: do the right thing. Truxton Trust delivers the highest level of personal service through its vastly experienced and credentialed team of professionals who provide comprehensive and customized financial solutions to individuals, their families and their business interests.
Investor Relations Andrew May 615-515-1707 [email protected] Media Relations Tamara Schoeplein 615-515-1714 [email protected]


Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Italy Fines Apple €98.6 Million Over App Store Dominance
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 



